Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial.
BACKGROUND
Antibiotic resistance decreases success of Helicobacter pylori (Hp) eradication. Recently published results show low rate of resistance and better compliance with moxifloxacin based regiments. AIMS&METHODS: Whether 7 days moxifloxacin with lansoprasole and amoxycillin can be compared with 10 days moxifloxacin with lansoprasole and amoxycillin according to moxifloxacin resistance. Patients with non-ulcer dyspepsia who had culture and histology positive Hp infection (n = 150) were randomly assigned into two groups. The first group (n = 75) received moxifloxacin 400 mg/d during 7 days and the other (n = 75) received moxifloxacin 400 mg/d during 10 days. All patients received amoxycillin 1 g twice daily, lansoprasole 30 mg twice daily. All Hp cultures were tested for sensitivity to moxifloxacin.


RESULTS
138 patients (92%) completed the study, 68 in the first group and 70 in the second. Eradication rates were 84% (57/68) and 76% (57/75) in the 7 days moxifloxacin group and 90% and 84% in the second group (63/70, 63/75) according to the PP and ITT analysis; p = n.s. Among 129 patients (86% of study group), 6% of strains were primary resistant to moxifloxacin. Eradication of moxifloxacin sensitive/resistant strains was 98%/66%, p < 0.05.


CONCLUSIONS
According to our results we recommend 7 days moxiflixacin based triple therapy.
Bago
Josip
J
Department of Gastroenterology, Internal Medicine Clinic, Clinical Hospital Sveti Duh, Zagreb, Croatia. josip.bago@zg.t-com.hr
Majstorović
Karolina
K
Belosić-Halle
Zeljka
Z
Kućisec
Nastja
N
Bakula
Vinko
V
Tomić
Monika
M
Bago
Petra
P
Troskot
Rosana
R
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D005260:Female; D024841:Fluoroquinolones; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011804:Quinolines / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin
Aliment Pharmacol Ther. 1999 Jun;13(6):775-80
10383507
Wien Klin Wochenschr. 2002 Jun 28;114(12):448-53
12422579
Gastroenterology. 1998 Nov;115(5):1272-7
9797384
Scand J Infect Dis. 2000;32(1):81-5
10716083
Arch Intern Med. 1999 Jul 26;159(14):1562-6
10421278
Aliment Pharmacol Ther. 2002 Jul;16(7):1269-75
12144576
Aliment Pharmacol Ther. 2007 Aug 1;26(3):495-500
17635384
Drugs. 2004;64(20):2347-77
15456331
Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1309-12
12468950
Aliment Pharmacol Ther. 2005 May 15;21(10):1241-7
15882245
Aliment Pharmacol Ther. 2002 Feb;16(2):167-80
11860399
Dig Liver Dis. 2007 Nov;39(11):1001-5
17889627
Helicobacter. 2009 Feb;14(1):61-5
19191898
Eur J Clin Microbiol Infect Dis. 2000 Jul;19(7):538-41
10968325
Helicobacter. 2006 Feb;11(1):39-45
16423088
Helicobacter. 2006 Oct;11(5):441-5
16961806
Antimicrob Agents Chemother. 2007 Jan;51(1):346-9
17043117
Symp Ser Soc Appl Microbiol. 2001;(30):134S-44S
11422569
Aliment Pharmacol Ther. 2000 Oct;14(10):1339-43
11012480
Int J Antimicrob Agents. 2007 Apr;29(4):389-96
17303392
Gut. 1998 Jul;43 Suppl 1:S61-5
9764043
Southeast Asian J Trop Med Public Health. 2006 Sep;37(5):970-4
17333742
Wien Klin Wochenschr. 2007;119(11-12):372-8
17634896
Gut. 2004 Sep;53(9):1374-84
15306603
Gut. 2007 Jun;56(6):772-81
17170018
Aliment Pharmacol Ther. 2000 Jul;14(7):901-10
10886046
Aliment Pharmacol Ther. 2002 Mar;16(3):527-32
11876707
N Engl J Med. 2002 Oct 10;347(15):1175-86
12374879